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ABSTRACT
Pulmonary reperfusion injury is a clinical 
syndrome with no single and recognized 
pathophysiologic mechanism. It is a ma-
jor cause of morbidity and mortality fol-
lowing lung transplantation, cardiogenic 
shock, or cardiopulmonary bypass. The 
underlying mechanisms remain uncertain. 
Lung inflammatory injury induced by li-
popolysaccharide, characterized by rapid 
sequestration of neutrophils in response to 
inflammatory chemokines and cytokines 
released in the lungs is an acceptable the-
ory. Structural or functional impairment 
of surfactant has been noted in pulmo-
nary reperfusion injury. The pathological 
changes may include bilateral pulmonary 
infiltrates, reduced lung compliance and 
worsening of gas exchange in the imme-
diate posttransplant period. Recruitment 
maneuver and high positive end-expir-
atory pressure can relieve postoperative 
respiratory failure, especially in the pa-
tient with reperfusion pulmonary edema 
after pulmonary thromboendarterectomy. 
Pharmaceutical agents, including inhaled 
nitric oxide, soluble complement receptor 
type 1, prostaglandin E1 and exogenous 
surfactant, attenuate pulmonary reperfu-
sion injury through distinct mechanisms. 
Extracorporeal membrane oxygenation 
and Novalung are temporary assistance in 
bridging to lung transplantation, stabiliza-
tion of hemodynamics during transplanta-
tion and treatment of severe lung dysfunc-
tion and primary graft failure. Modulation 
of heme oxygenase-1 expression, ischemic 
conditioning and gene therapy are future 
directions for pulmonary reperfusion in-
jury management.
Key words: cardiopulmonary bypass, pul-
monary hypertension, respiratory insuffi-
ciency
INTRODUCTION
Pulmonary reperfusion injury is a com-
mon clinical problem secondary to severe 
shock, cardiopulmonary bypass (CPB) and 
lung transplantation, etc. (1) It is a major 
cause of morbidity, predominantly pri-
mary graft dysfunction (PGD) and mor-
tality following lung transplantation. (2,3) 
Ischemia and reperfusion are two distinct 
events due to the fact that the resultant 
pathological changes of the lungs are dif-
ferent. Reperfusion injury is a worsen-
ing lesion developing from the ischemia 
injury. (4) Pulmonary reperfusion injury 
is characterized by non-specific alveolar 
damage, lung edema and hypoxemia oc-
curring within 72 hours. (5) After CPB, 
lung disturbances, including increased 
lung permeability and pulmonary vascular 
resistance, as well as lung surfactant chang-
es, develop. (6)
MECHANISMS
Mechanisms of pulmonary reperfusion 
injury have been extensively studied. 
Complete and prolonged lung anoxia for 
up to several hours is unavoidable during 
lung transplantation. (7) Lung injury of-
ten occurs within the first few seconds to 
hours after reperfusion, as evidenced by 
experiments in different models. (8) How-
ever, the exact pathogenesis of pulmonary 
reperfusion injury remains uncertain. 
Lung inflammatory injury induced by li-
popolysaccharide characterized by rapid 
sequestration of neutrophils in response to 
inflammatory chemokines and cytokines 
released in the lungs is an acceptable theo-
ry. (9) Pulmonary reperfusion injury after 
lung transplantation is also mediated by 
oxidative stress-dependent mechanisms 
involving nicotinamide adenine dinucleo-
tide phosphate oxidase and by apoptosis, 
(10) and the central role of nuclear factor-
κB in the induction of lung inflammatory 
injury is now emerging. (11) In lung tissue 
biopsies obtained from 20 consecutive hu-
man lungs for transplantation, apoptotic 
cells increased in number after graft rep-
erfusion in a time-dependent manner. (12) 
In a rat lung transplant model, cell viability 
determinations revealed that lung function 
decreased significantly with increasing 
preservation time and that the necrotic cell 
percentage was inversely correlated with 
posttransplant graft function. (2) The peak 
apoptotic rate of pneumocytes occurred 2 
hours after reperfusion in rats with single 
lung transplantation. (13)
Structural or functional impairment of 
surfactant has been noted in pulmonary 
reperfusion injury. (14) In contrast, the 
surfactant changes in adult respiratory dis-
tress syndrome patients were considered to 
be caused by lung dysfunction. (9) Nuclear 
factor-κB is a rapid response transcription 
factor that activates genes responsible for 
the mediators of inflammation. In a por-
cine transplantation model, nuclear factor-
κB played a central role in triggering the 
pathways for lung inflammatory injury. 
Activation of nuclear factor-κB occurred 
30 minutes and 1 hour after transplanta-
tion and fell to near baseline levels after 4 
hours. Pyrrolidine dithiocarbamate, a po-
tent inhibitor of nuclear factor-κB, given 
to the lung graft during organ preservation 
(40 mmol/L) effectively inhibited nuclear 
factor-κB activation and significantly im-
proved lung function. (11) Heat shock pro-
tein 70 has been shown to protect against 
lung injury. (15) In rabbits with depletion 
of neutrophils, pulmonary ischemia-reper-
fusion injury occurred when the ischemic 
lungs were deflated but did not occur when 
the ischemic lungs were inflated. (1) Oxi-
dative stress and apoptosis may also play 
an important role in the development of 
pulmonary reperfusion injury. (10)
Animal experiments revealed that CPB 
caused a threefold increase in the exter-
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nal pulmonary protein leak index, and 
slightly increased extravascular lung wa-
ter. Moderately elevated left atrial pressure 
may increase lung water >50% after CPB 
compared with control, but peak endo-
toxin and minimum total complement 
CH50 levels did not. (16) An early phase 
of endotoxin release due to vasoconstric-
tion could be noted during CPB. The endo-
toxin concentrations at CPB termination 
relied on early vasoconstriction, duration 
of aortic crossclamping and hypo-oncotic 
hemodilution. (17) However, a prospective 
clinical study revealed that off-pump coro-
nary artery bypass does not confer major 
protection from postoperative pulmonary 
dysfunction in comparison to convention-
al coronary artery bypass grafting under 
CPB. (18) It hinted that CPB might not 
be a direct causative etiology responsible 
for postoperative pulmonary dysfunction. 
Nevertheless, normothermic CPB may re-
duce intrapulmonary shunt function and 
alveolar-arterial oxygen and carbon diox-
ide gradients and therefore may preserve 
lung function. (19)
Prolonged pulmonary ischemia and sub-
sequent reperfusion injury occur during 
procedures such as pulmonary endarterec-
tomy, hypothermic circulatory arrest and 
lung transplantation. Extrapulmonary is-
chemia-reperfusion can also contribute to 
lung injury. (20) Inflammatory cytokines 
including interlukin-8 (21) or matrix met-
alloproteinase 9 (22) may be upregulated 
secondary to donor lung injury or surgi-
cal trauma. The inflammatory responses 
also link to interlukin-1β, which  induces 
the action of the cicloxigenase (COX) and 
the expression of the inductive nitric oxide 
syntax (iNOS). (23) It also increases the 
expression of other cytokines such as in-
terlukin-6 as well TNF-α. (23,24)
Pulmonary thromboendarterectomy is a 
potentially curative procedure in chroni-
cally thromboembolic pulmonary artery 
hypertension. The early mortality rate in 
54 patients between 1989 and 1992 was 
22.2% (12/54) and currently below 7%. 
(25) Reperfusion pulmonary edema can 
be a result of the development of hypox-
emia and radiological infiltrates in areas of 
reperfused endarterectomy. (26) Levinson 
et al. (27) reported 22 patients had post-
operative reperfusion pulmonary edema, 
which developed within 72 hours follow-
ing pulmonary thromboendarterectomy.
Diagnosis
Bilateral pulmonary infiltrates, reduced 
lung compliance and worsening of gas ex-
change in the immediate posttransplant 
period are helpful to the diagnosis. (28) 
Medical imaging including chest radiogra-
phy and chest computed tomography may 
show characteristic pulmonary changes of 
graft capillary leakage and infiltrates, pleu-
ral effusions or lung edema on chest radi-
ography and chest computed tomography. 
(29)
PREVENTION
Pulmonary preservation for transplanta-
tion is associated with ischemia-reperfu-
sion injury resulting in endothelial cell and 
surfactant dysfunction. (30) The preserva-
tion method is pulmonary artery perfusion 
with a preservation solution at 4°C, which 
may cool the tissue evenly and remove 
blood from the pulmonary vascular bed, 
preventing thrombosis and attenuating 
cellular injury caused by macrophages and 
neutrophils. (31) In a rat model of double 
lung transplantation, a comparative study 
of lung preservation solutions revealed low 
potassium dextran provided superior graft 
function to Euro-Collins, low potassium 
Euro-Collins and University of Wisconsin 
solution after extended ischemia. (32) In a 
porcine lung transplantation model, after 
24 hours of cold ischemia, low potassium 
dextran or Celsior solution provided safe 
pulmonary preservation, while surfactant 
activity was affected to the same extent. 
Celsior solution showed slightly superior 
endothelial preservation. (30) The largest 
cohort study of adult lung transplanta-
tion survival revealed that low potassium 
dextran was superior to University of Wis-
consin solution, the latter increasing the 
risk of 1-year mortality in high-risk lung 
transplant recipients. (33) Haverich et al. 
(34) found that lungs flushed with a high 
perfusate volume given at a high flow rate 
(60 mL/kg given in 4 minute) resulted in 
significantly better pulmonary cooling 
and better lung function after reperfusion 
in comparison to low perfusate volume 
given at a low flow rate (20 mL/kg given 
in 6 minute) with a low perfusate volume 
given at a high flow rate (20 mL/kg given 
in 1.3 minute). Alternative studies demon-
strated that lung function was significantly 
better after reperfusion if the lungs were 
initially flushed with a temperature of 15-
20°C instead of ≤10°C as observed in small 
animals and surface cooling of the inflated 
lungs. (35) Steen et al. (36) recommended 
that if the temperature of the flush solution 
was kept at room temperature, the lungs 
should be kept collapsed during cold stor-
age to reduce core temperature quicker by 
avoiding the insulating effect of air.
TREATMENT
Recruitment maneuver
Recruitment maneuver and high positive 
end-expiratory pressure can relieve post-
operative respiratory failure, especially in 
the patient with reperfusion pulmonary 
edema after pulmonary thromboendar-
terectomy for chronic pulmonary throm-
boembolism. With recruitment maneu-
vers: positive end-expiratory pressure, 
30 cmH2O, peak inspiratory pressure, 42 
cmH2O and respiratory rate, 15 breaths/
min for 1 min with a high positive end-
expiratory pressure of 15 cmH2O, the rep-
erfusion pulmonary edema can be gradu-
ally relieved, followed by improvement of 
oxygenation and pulmonary hypertension. 
(37)
PHARMACOLOGICAL THERAPY
1. Inhaled nitric oxide (iNO)
iNO can mediate pulmonary vasodilata-
tion and improve pulmonary function in 
patients with lung injury, treatment of lung 
allograft recipients with iNO may amelio-
rate ischemia-reperfusion injury, thereby 
improving perioperative pulmonary func-
tion and diminishing ventilatory support 
requirements. (38) iNO suppressed pul-
monary hypertension after reperfusion, 
and might enhance suppression of oxygen 
free radicals and therefore may be thera-
peutically useful after lung transplanta-
tion. (39) The administration of iNO dur-
ing lung transplantation was proposed as 
a possible therapeutic treatment to prevent 
or attenuate PGD. There was evidence that 
iNO in patients with PGD might improve 
oxygenation and reduce pulmonary hyper-
tension without altering systemic vascular 
resistance. This suggested that iNO could 
prevent the need for extracorporeal mem-
brane oxygenation during the hypoxic 
phase of primary graft failure. (40) Experi-
ments proved that iNO attenuated apop-
tosis in ischemia-reperfusion injury of the 
rabbit lung. The number of apoptotic cells 
was remarkably reduced in the iNO group 
than in the control after 120-minutes of 
reperfusion (1.76% vs. 2.87%, p < 0.01). 
(41) Clinical studies of lung transplant pa-
tients showed iNO may improve hemody-
namic parameters. (42)
2. Prostaglandins
Prostaglandin E1 has been demonstrated 
to reduce ischemia-reperfusion injury fol-
lowing lung transplantation. (43) In a rat 
single lung transplant model, prostaglan-
din E1 does not decrease the amount of 
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apoptosis after reperfusion and does not 
significantly upregulate B-cell lymphoma 
2. Administration of prostaglandin E1 
during the reperfusion period reduces 
ischemia-reperfusion injury through a 
mechanism mediated by a shift between 
pro- and anti-inflammatory cytokine re-
leases. (43) Experiments of reperfusion 
on ischemic lung injury in an in situ rab-
bit model showed that prostaglandin E1 
may exert a direct cytoprotective effect 
other than by its vasodilating properties 
or the known effects of prostaglandin E1 
on platelets, neutrophils, or tumor necrosis 
factor suppression. (44)
3. Soluble complement receptor type 1 
(sCR1)
Soluble complement receptor type 1 (sCR1) 
is a powerful inhibitor of complement acti-
vation. sCR1 protects the myocardium and 
lungs from some of the deleterious effects 
of CPB. The significantly higher arterial 
partial tension of oxygen after CPB in the 
sCR1 animals suggests that sCR1 protects 
lung function. Gillinov et al. (45) reported, 
in young pigs, that after CPB, pulmonary 
vascular resistance increased by 338% in 
control but only by 147% in sCR1-treated 
animals. This was in line with the results 
reported by Chai et al. (46) from neonatal 
pigs, i.e., after CPB pulmonary vascular 
resistance increased by 350% and 120% in 
the control and sCR1 groups, respectively.
4. Platelet-activating factor antagonists
Platelet activating factor is an inflamma-
tory mediator produced by a variety of 
cells in response to inflammatory and im-
mune stimuli, and is implicated in a wide 
range of pathological conditions includ-
ing ischemia-reperfusion injury after lung 
transplantation. (47) Platelet-activating 
factor antagonists reduce pulmonary rep-
erfusion injury by inhibition of neutrophil 
accumulation, eosinophilic inflammation 
and chemotaxis. (48) Platelet activating 
factor antagonists given before organ rep-
erfusion significantly improve lung func-
tion after lung transplantation. (49)
5. Surfactant
Surfactant dysfunction occurs during 
ischemia-reperfusion injury. Exogenous 
surfactant therapy improves lung func-
tion by stabilizing and enhancing the ac-
tive endogenous surfactant, (50) and de-
creasing the development of intraalveolar 
edema and atelectasis, but worsening the 
peribronchovascular edema. (51) Delivery 
methods of exogenous surfactant remain 
challenging, but bronchoscopic instillation 
to aerosolized surfactant is preferred. (7)
EXTRACORPOREAL MEMBRANE 
OXYGENATION
Indications for extracorporeal membrane 
oxygenation use in lung transplantation 
are temporary assistance as a bridge to 
transplantation, stabilization of hemody-
namics during transplantation, and treat-
ment of severe lung dysfunction and PGD 
after transplantation. However, patient 
survival was significantly reduced with the 
use of extracorporeal membrane oxygena-
tion, although it can provide acceptable 
support for PDG after lung transplanta-
tion. (52-54)
NOVALUNG
Novalung is an evolving support system to 
bridge patients with idiopathic pulmonary 
hypertension to lung transplantation with 
a modified surgical technique for left pul-
monary artery-to-left atrium bypass. With 
the application of Novalung, pulmonary 
artery systolic pressures can be decreased 
and the patient’s oxygenation improved. 
(55)
FUTURE DIRECTIONS
Endogenous expression of heme oxy-
genase-1 represents a transcriptional 
response to oxidative stress. Heme oxy-
genase-1 provides potent cytoprotective 
effects. Enhanced endogenous heme oxy-
genase-1 and its downstream mediators 
protect against the sequel of ischemia-
reperfusion injury. (56) In order to obtain 
biological adaptation, tissues are exposed 
to a brief insult, by which tolerance of or-
gans to a subsequent reperfusion injury is 
anticipated, and this process is termed as 
preconditioning. (57) Ischemic precondi-
tioning is usually achieved by brief peri-
ods of ischemia and reperfusion before a 
prolonged period of ischemia and it can 
reduce the ischemic-reperfusion injury 
in solid organs. (58) Nowadays, precon-
ditioning has been expanded to hyper-
thermic preconditioning by increased 
temperature and chemical precondition-
ing by administration of pharmacologic 
agents. (57) Ischemic preconditioning of 
guinea pig lungs mounted on a modified 
Langendorff perfusion resulted in reduced 
malondialdehyde and glutathione levels 
and less elevated pulmonary artery pres-
sure. (59) The mechanism seemed to be 
at least partly by stimulating autophagy. 
(59) Recent research results also revealed 
that ischemic postconditioning attenu-
ates lung reperfusion injury and reduces 
systemic proinflammatory cytokine re-
lease via heme oxygenase-1. (60) Gene 
therapy, such as transfection of the gene 
coding for transforming growth factor β1 
and interleukin-10, were proved to reduce 
ischemia-reperfusion injury and improve 
lung function in a rat single lung trans-
plant model. (61,62) It has been noted that 
in rat lung transplantation models, a mini-
mal 12-hour transtracheal administration 
of interleukin-10 to the donor lungs may 
improve post-transplant lung functions. 
(63) Human lung protection by gene ther-
apy will come to true soon.
CONCLUSIONS
Pulmonary reperfusion injury is a ma-
jor cause of PGD and mortality following 
lung transplantation, cardiogenic shock or 
CPB. The underlying mechanisms remain 
uncertain. Lung inflammatory injury in-
duced by lipopolysaccharide, character-
ized by rapid sequestration of neutrophils 
in response to inflammatory chemokines 
and cytokines released in the lungs is an 
acceptable theory. The management strat-
egies for pulmonary reperfusion injury 
are similar to those for adult respiratory 
distress syndrome with stresses on phar-
maceutical agents including inhaled nitric 
oxygen, prostaglandin E1 and surfactant 
replacement therapy for the former, and 
on ventilation treatment for worsening 
respiratory mechanics for the latter.
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